BetterLife Pharma

Omineca Announces $2 Million Brokered Financing of Flow-Through Units

NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

Omineca Mining and Metals Ltd. (" Omineca " or the " Company ") (TSXV:OMM) is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent and sole bookrunner (the " Agent ") in connection with a brokered, best-efforts basis, private placement offering (the " Offering ") of flow-through units of the Company (each, a " FT Unit ") at a price of $0.11 per FT Unit, for gross proceeds of up to $2,000,000.

Each FT Unit shall be comprised of one common share of the Company (a " Common Share ") that will qualify as "flow-through shares" within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the " Tax Act ") and one purchase warrant of the Company (a " Warrant "). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.14 for a period of 36 months from Closing (as defined herein).

The Company will grant the Agent an option (the " Agent's Option ") to increase the size of the Offering by up to 15% of the number of FT Units by giving written notice of the exercise of the Agent's Option, or a part thereof, to the Company at any time up to 48 hours prior to the Closing Date.

The Offering will be conducted pursuant to the amendments to National Instrument 45-106 – Prospectus Exemptions (" NI 45-106 ") set forth in Part 5A thereof (the " Listed Issuer Financing Exemption ") to purchasers resident in Canada, except Québec. The FT Units offered under the Listed Issuer Financing Exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws.

The gross proceeds from the sale of FT Units will be used for exploration expenses on the Company's Wingdam gold project in British Columbia as Canadian exploration expenses as defined in paragraph (f) of the definition of "Canadian exploration expense" in subsection 66.1(6) of the Tax Act and "flow through mining expenditures" as defined in subsection 127(9) of the Tax Act that will qualify as "flow-through mining expenditures" (the " Qualifying Expenditures "), which will be incurred on or before December 31, 2024 and renounced with an effective date no later than December 31, 2023 to the initial purchasers of FT Units.

The Offering is anticipated to close on or about March 22, 2023 (" Closing "), or such later date as the Company may determine. The Closing is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and other approvals, including the approval of the TSX Venture Exchange. Omineca advises that the insiders of the company may participate in the Offering, which will be completed pursuant to available related party exemptions under Multilateral Instrument 61-101.

At Closing, the Company will pay to the Agent a 6.5% cash commission based on the aggregate gross proceeds arising from the Offering (including in respect of any exercise of the Agent's Option). The Company will also grant the Agent, on the date of Closing, non-transferable broker warrants (the " Broker Warrants ") equal to 6.5% of the total number of FT Units sold pursuant to the Offering (including in respect of any exercise of the Agent's Option). Each Broker Warrant shall entitle the holder thereof to purchase one unit of the Company (comprising of a Common Share and a Warrant) at an exercise price of $0.11 per unit for a period of 36 months following the Closing.

There is an offering document related to the Offering that can be accessed under the Company's profile at www.sedar.com and on the Company's website at www.ominecaminingandmetals.com. Prospective investors should read this offering document before making an investment decision.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the " 1933 Act ") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

About Omineca Mining and Metals Ltd.

Omineca Mining and Metals Ltd.'s flagship Wingdam gold exploration and placer recovery project is located along the Barkerville Highway 45 km east of the City of Quesnel. The Wingdam Property includes mineral tenures totaling over 61,392 hectares (613 square kms) and in excess of 15 linear kilometers of placer claims, both encompassing the Lightning Creek valley where topographic conditions created thick layers of overburden, which preserved a large portion of a buried paleochannel containing placer gold-bearing gravels. Omineca also has an exploration and diamond drill program currently underway exploring for the potential multiple hard rock sources of the placer gold at Wingdam.

Qualified Person

All scientific and technical information in this news release has been prepared by, or approved by Stephen Kocsis, P.Geo., Lead Geologist. Mr. Kocsis is a qualified person for the purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects.

For further information, please contact:

Tom MacNeill
President and CEO
306-653-2692

Forward Looking Statements

This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. "Forward-looking information" includes, but is not limited to, statements with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, including the expectation that the Offering will close in the timeframe and on the terms as anticipated by management. Generally, but not always, forward-looking information and statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. These forward‐looking statements or information relate to, among other things: the intended use of proceeds from the Offering, the expected closing date of the Offering, and the incurrence of Qualifying Expenditures.

Such forward-looking information and statements are based on numerous assumptions, including among others, that the Company will complete Offering in the timeframe and on the terms as anticipated by management. Although the assumptions made by the Company in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause actual results to differ materially from the Company's plans or expectations include risks relating to the failure to complete the Offering in the timeframe and on the terms as anticipated by management, market conditions and timeliness regulatory approvals. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information.



News Provided by GlobeNewswire via QuoteMedia

BETR:CNX
The Conversation (0)
BetterLife Pharma

BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR OTCQB: BETRF FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that, an article titled "Non-hallucinogenic LSD derivative reduces depression symptoms in preclinical studies," based on BetterLife's lead candidate BETR-001 (2-bromo-LSD) was published by Drug Discovery & Development on March 22, 2023.

The Drug Discovery & Development article describes and adds further comments to the positive data and extensive pharmacological characterization of BETR-001 which were published recently in the peer-reviewed journal Cell Report s. These studies were performed by BetterLife in collaboration with several leading scientists in this field: Dr. Adam L. Halberstadt (University of California San Diego, USA), Dr. Argel Aguilar-Valles (Carleton University, Canada), and Dr. John D. McCorvy (Medical College of Wisconsin, USA).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Betterlife Pharma

Betterlife Publishes Promising Results from a Study Titled "A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders"

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR OTCQB: BETRF FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled "A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders" has been published in the peer-reviewed journal of Cell Report .

The study expands on previously reported positive data by performing an extensive pharmacological characterization of BETR-001 in comparison with LSD. The results show distinct central nervous system aminergic receptors pharmacological differences between BETR-001 versus LSD. These include 5-HT2A receptor partial agonism and lack of psychedelic-like effects in vivo for BETR-001 in contrast to LSD. Further, the study demonstrates lack of 5-HT2B agonism for BETR-001 in contrast to the 5-HTB agonism caused by LSD, and therefore a projected safer cardiovascular profile for BETR-001. Finally, the study shows BETR-001 induces neuroplasticity both in vitro and in vivo while promoting active coping behavior in mouse models of depression and anxiety.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BetterLife Pharma

BetterLife Announces Pricing of Proposed Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR OTCQB : BETRF FRA: NPAU ) an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has priced its previously announced private placement offering (the "Offering") of units of the Company ("Units"). Pursuant to the Offering, the Company will issue Units at a price of $0.10 per Unit for total minimum aggregate gross proceeds of $1,500,000 and maximum gross proceeds of $5,000,000. Each Unit is comprised of one common share of the Company (a "Common Share") and one Common Share purchase warrant of the Company (each whole Common Share purchase warrant, a "Warrant"). Each Warrant will entitle the holder thereof to acquire one Common Share for a period of 60 months from the date of issuance of such Warrant, at an exercise price of $0.15, subject to and in accordance with the terms and conditions of the warrant indenture to be entered into between the Company and Endeavor Trust Corporation (the "Warrant Indenture").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BetterLife Pharma

BetterLife Announces Offering of Units

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR OTCQB : BETRF FRA: NPAU ) an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce a private placement offering (the "Offering") of units of the Company ("Units"), comprising of one common share of the Company and one common share purchase warrant of the Company. Bloom Burton Securities Inc. ("Bloom Burton" or the "Agent") is acting as the sole placement agent for the Offering. The number of Units to be distributed, the price of each Unit and the exercise price of each common share purchase warrant will be determined by negotiation between the Company and Bloom Burton in the context of the market with final terms to be determined at the time of pricing.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR  OTCQB: BETRF FRA: NPAU ), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce the engagement of Bloom Burton Securities Inc. ("Bloom Burton") for strategic advisory services to support BetterLife's growth and development initiatives towards clinical trials.

"We are very excited to be working with Bloom Burton, Canada's leading healthcare investment banking firm," said Ahmad Doroudian, CEO of BetterLife. "Bloom Burton has extensive understanding of the overall biotechnology and healthcare landscape and the emerging psychedelics space specifically, which will help advance our clinical trial initiatives and accomplish our financing needs."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Reports First Quarter 2024 Results

Branded revenue growth of 37.0% in the U.S. and pro forma 80.2% in China reflects strength of strategic growth plan in the Company's two largest markets

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported its first quarter results for the period ended March 31, 2024. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Medical pills branded with Canadian flag.

Canadian Pharma Stocks: 5 Biggest Companies in 2024

The Canadian pharmaceutical market is the eighth largest in the world and accounts for 2.2 percent of the global prescription drug market. But what are the biggest Canadian pharma stocks?

Many successful Canadian drug companies are in the late stages of clinical trials, and some have also have brought pharmaceutical products to market or set up partnerships to develop products, both at home and globally.

According to data compiled by the Canadian government, the country's pharma companies are involved in research and development to bring new or improved patented therapies to market, and are also developing generic versions of bio-equivalent drugs whose patents have expired. Additionally, gene and cell therapies and nanomedicines are emerging fields in the Canadian pharmaceutical market.

Keep reading...Show less

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –

– Top-line data readout for VERITAC-2 remains on-track for 2H 2024 –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Jamieson Wellness Inc. Announces Date of First Quarter 2024 Financial Results and Conference Call

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company will release its first quarter 2024 financial results after the market close on Thursday, May 9, 2024. The Company will host a conference call for investors at 5:00 p.m. Eastern Time to discuss the first quarter 2024 results.

The call can be accessed live over the telephone by dialing 1-800-717-1738 from Canada and the U.S. or 1-646-307-1865 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 1179130 and it will be available until Thursday, May 23, 2024.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Pill package with up arrow.

Top 3 Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.

Three months into 2024, market watchers are keeping a close eye on pharma companies vying for the next major innovation.

Here the Investing News Network lists the top Canadian pharma stocks trading on the Toronto Stock Exchange (TSX) and the TSX Venture Exchange (TSXV). Companies considered had market caps above C$100 million and were arranged based on year-on-year performance. All data was compiled on April 16, 2024, using TradingView’s stock screener.

Keep reading...Show less

Latest Press Releases

Related News

×